Drugs / VR942
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02473939 | Jun 2015 → Apr 2016 | asthma | Vectura Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VR942 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02473939 ↗ |
| Modality | Monoclonal antibody | “inhaled interleukin-13 monoclonal antibody fragment VR942” PMID 30146344 ↗ Aug 2018 |
| Route | Inhaled | “single inhaled dose of VR942 0.5, 1.0, 5.0, 10, or 20 mg” PMID 30146344 ↗ Aug 2018 |